Pharmaceuticals

Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients

SUZHOU, China, March 11, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced today top-line results from its investigator-initiated Brazil trial evaluating the efficacy of Proxalut...

2021-03-11 14:54 4880

Impact Therapeutics Announced First-Patient-Dose of Wee1 Inhibitor IMP7068 in the U.S.

SHANGHAI, March 10, 2021 /PRNewswire/ -- Impact Therapeutics announced today that the first patient was recently dosed in the first-in-human Phase 1 clinical study of Wee1 Inhibitor IMP7068 inthe United States. This is a Phase 1, open-label, multi-center, dose escalation and expansion study to e...

2021-03-10 21:14 1592

Arctic Vision Announces Completion of Over US$100 Million Series B Financing to Accelerate Portfolio Expansion, Clinical Development and Commercialization

SHANGHAI, March 9, 2021 /PRNewswire/ -- Arctic Vision, a China-based clinical-stage ophthalmology company focused on developing innovative therapies for pan-ocular diseases, today announced the completion of overUS$100 million Series B financing. The Series B round was led by Loyal Valley Capital...

2021-03-10 08:00 1934

Alphamab Received U.S. FDA IND Clearance to Initiate A Phase II Pivotal Clinical Trial of KN046 (KN046-205,ENREACH-Thymic) in the U.S.

SUZHOU, China, March 9, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application (IND) to initiate an open label, multi-center phase II pivotal clinical study (clinical trial ...

2021-03-09 20:00 3561

Nippon Express (Malaysia) Obtains GDP Certification for Domestic Transport Services

TOKYO, March 9, 2021 /PRNewswire/ -- Nippon Express (Malaysia) Sdn, Bhd. (hereinafter, "NE Malaysia"), a local subsidiary of Nippon Express Co., Ltd. based inTokyo, has obtained Good Distribution Practice (GDP) certification effectiveThursday, January 14, 2021 for its Kuala Lumpur International A...

2021-03-09 15:00 1581

Yangtze River Pharmaceutical (Group) Co., Ltd. Won the 2021 EFQM Global Award

TAIZHOU, China, March 8, 2021 /PRNewswire/ -- At 19:20 on March 4, 2021 (Beijing time), the results of the 2021 EFQM Global Award were announced. Yangtze River Pharmaceutical (Group) Co., Ltd. fromChina was on the list, which represents that its quality management level has been aligned with that...

2021-03-09 11:19 1399

Winhealth Pharma and Merz Collaborate on Hepa-Merz® to benefit patients with liver disease in China

HANG ZHOU, China, March 8, 2021 /PRNewswire/ -- On Feb. 26th, 2021, Hongkong Winhealth Pharma Group Co., Ltd (hereinafter referred to as "Winhealth Pharma") signed a strategic cooperation agreement with Merz Pharmaceuticals GmbH (hereinafter referred to as "Merz"). The strategic cooperation betwe...

2021-03-09 10:00 3140

CMAB Biopharma Congratulates Partner Junshi Biosciences on NMPA Acceptance of Application for a Clinical Trial of its PD-1/TGF-β Bifunctional Fusion Protein

SUZHOU, China, March 7, 2021 /PRNewswire/ -- Recently, CMAB Biopharma (Suzhou) Inc's ("CMAB") partner Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences") (HK: 1877; SH: 688180), announced that a clinical trial application for its PD-1/TGF-β bifunctional fusion protein JS201 injection (J...

2021-03-08 11:41 1651

Adlai Nortye Announces Formation of its New Scientific Advisory Board

HANGZHOU, China, March 7, 2021 /PRNewswire/ -- Adlai Nortye, a global clinical-stage biopharmaceutical company, today announced the formation of its new Scientific Advisory Board (SAB) comprised of five internationally renowned experts. The SAB includesRonald M. Evans, PhD (Member of the US Natio...

2021-03-08 09:00 1662

Proxalutamide Phase III Clinical Trial for the Treatment of COVID-19 Patients Approved by FDA

SUZHOU, China, March 5, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to announce that the Investigational New Drug (IND) application of the phase III clinical trial of Proxalutamide's treatment of male COVID-19 outpatients has been approved by the United States Food ...

2021-03-05 21:00 7337

ABclonal Biotechnology Acquires Yurogen Biosystems to Better Serve Diagnostic and Pharmaceutical Researchers Worldwide

BOSTON, March 5, 2021 /PRNewswire/ -- ABclonal Biotechnology Co., Ltd., a global life science tools and services provider, acquires Yurogen Biosystems LLC, a contract research organization dedicated to monoclonal antibody discovery using single-B-cell-based SMabTM platform, to better serve resea...

2021-03-05 20:00 2876

Mayne Pharma launches another generic oral contraceptive

ADELAIDE, Australia, March 4, 2021 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the commercial launch of a generic version of ORTHO-CEPT® (desogestrel and ethinyl estradiol 0.15 mg / 0.03 mg) tablets to customers in the US. This is the fourth oral contraceptive la...

2021-03-05 05:34 4666

Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States

TAIPEI, March 4, 2021 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO) ("Foresee") announced today that it has entered into an exclusive license agreement with Intas Pharmaceuticals ("Intas") for the US commercialization of Foresee's novel FP-001 program, Leuprolide Mesylate Injectable Suspensi...

2021-03-04 23:00 3011

Yuyu Pharma Publishes History for 80th Anniversary

SEOUL, South Korea, March 3, 2021 /PRNewswire/ -- Yuyu Pharma (KRX: 000220, CEO Robert Wonsang Yu), in anticipation of the 80th anniversary of its establishment onFebruary 28th, 2021, published its history of challenges and changes over the past 80 years. The history is told in storytelling forma...

2021-03-03 22:00 1889

I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021

SHANGHAI and GAITHERSBURG, Md., March 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will report financial results for the full year ...

2021-03-03 21:00 5366

SciClone Pharmaceuticals Officially Listed on the Main Board of the Hong Kong Stock Exchange

SHANGHAI, March 3, 2021 /PRNewswire/ -- SciClone Pharmaceuticals (Holdings) Limited ("SciClone Pharmaceuticals" or "SciClone") was officially listed today on the Main Board of The Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange" or "HKEx") under stock code: 6600. In the initial of...

2021-03-03 16:43 7663

CMAB Biopharma Congratulates Partner Innovent Biologics on FDA Clearance of IND Application of its COVID-19 Antibody Project

SUZHOU, China, March 2, 2021 /PRNewswire/ -- CMAB Biopharma (Suzhou) Inc ("CMAB") congratulates its partner Innovent Biologics, Inc ("Innovent") (1801.HK) on the U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for its antibody candidate which ta...

2021-03-03 11:12 1459

CMAB Biopharma Congratulates QureBio on FDA Clearance of IND Application for Claudin18.2/PD-L1 Bispecific Antibody

SUZHOU, China, March 2, 2021 /PRNewswire/ -- Recently, CMAB Biopharma (Suzhou) Inc's ("CMAB") partner QureBio Ltd ("QureBio") has announced its innovative drug Q-1802 received United States Food and Drug Administration (FDA) clearance for an Investigational New Drug (IND) application. This applic...

2021-03-02 13:43 1576

China Biologic Announces Shareholders' Approval of Merger Agreement

BEIJING, March 1, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that, at an extraordinary general meeting (the "EGM") held today, the Company...

2021-03-01 21:00 10069

Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index

SHANGHAI and HONG KONG, Feb. 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...

2021-03-01 08:00 5923
1 ... 112113114115116117118 ... 131